Biomedical Computer Technologies, a drug and healthcare products wholesaler, posted operating profit of HUF 86,000 on revenue of HUF 800,000 for the first half of 2011, its unaudited HAS financial report shows.
All revenue came from domestic sales.
Biomedical Computer Technologies, which was established in November 2010, had no revenue in 2010 and booked a HUF 22,000 loss.
Biomedical shares have been listed in category "B" of the Budapest Stock Exchange since June 29 this year.
Biomedical Computer Technologies decided to list its shares in order to raise capital to fund the development of an invention gained through its earlier merger with Hydro-Tar that replaces battery acid with hydrogen, company CEO Sandor Kovacs told MTI on June 1.
Biomedical said it plans to list its shares onto the Frankfurt stock exchange and is making efforts - still using its own funds - to produce the prototype of a hydrogen-fuelled car.